NEW EVENT! Cutting-edge Trends for Life Sciences at PACK EXPO Southeast
Discover all the latest packaging solutions for life sciences products at the all-new PACK EXPO Southeast in Atlanta, GA, March 10-12, 2025

Spasm Medicine Goes From $40 to $34,000

Mallinckrodt will pay $100 million settlement after raising price of infantile spasm medication 85,000%.

H.P. Acthar Gel / Photo: National Library of Medicine
H.P. Acthar Gel / Photo: National Library of Medicine

A Washington Post article from January 18th detailed Mallinckrodt Pharmaceuticals’ anti-competitive behavior to preserve its monopoly on H.P. Acthar Gel, a rare-disease drug used to treat infantile spasms. In 2001, Questcor bought Acthar Gel, which once sold for $40 a vial, for $100,000 plus royalties. Questcor was then bought by Mallinckrodt in 2014 after raising the price to over $34,000 a vial. The drug brought in over $1 billion in revenue in 2015.

The 85,000% price hike wasn’t the focus of the federal and state investigations though. Rather, the FTC focused on Questcor’s acquisition of a synthetic version of Acthar to forestall future competition. Outside the U.S., Novartis was selling Synacthen, a similar medicine used to treat infantile spasms among other similar conditions. Questcor bought the U.S. rights for around $135 million.

While the drug company admits no wrongdoing, it will pay out $100 million in the settlement and has agreed to license Synacthen to a competitor approved by the FTC.

INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
Read More
INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast